Fetal Bovine Serum Virus Testing and Supply Chain Risk Control from the Perspective of Regulatory Compliance

Regulations and Standards Requirements for Fetal Bovine Serum Virus Testing

In the fields of biopharmaceuticals, vaccines and cell therapy, fetal bovine serum is a key raw material, and its quality must meet relevant pharmacopoeias, guidelines and industry standards.Suppliers are generally required to carry out the necessary screening for viral contamination and provide proof accordingly.Although the specific terms vary from country to country, the trend is to enhance source traceability of raw materials, virus clearance/inactivation verification, and batch detection awareness.When selecting products, users should pay attention to whether the detection item covers the target virus recommended by the regulations and whether the method meets the current prevailing norms.

Position of Virus Testing in Vendor Audit

In supply chain risk control, virus detection results are one of the important dimensions for evaluating supplier capabilities.Audits typically look at more than one report and focus on:

Health status and traceability of cattle in raw material collection areas;

Whether the production process has measures to reduce the risk of introduction of exogenous viruses;

Records of qualifications, method validation and quality control of testing laboratories;

Nonconforming batch processing and deviation investigation mechanism.

Through systematic audits, users can more comprehensively assess the viral risk control level of fetal bovine serum suppliers, rather than relying on a single test conclusion.

Interpretation of test results and risk communication

The results of the fetal bovine serovirus test report need to be interpreted professionally.For example, positive PCR may indicate residual nucleic acid, but not necessarily equivalent to infectious intact viral particles; negative knots in cell culture